Laura Borodyansky

576 total citations
28 papers, 470 citations indexed

About

Laura Borodyansky is a scholar working on Oncology, Toxicology and Molecular Biology. According to data from OpenAlex, Laura Borodyansky has authored 28 papers receiving a total of 470 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Oncology, 12 papers in Toxicology and 9 papers in Molecular Biology. Recurrent topics in Laura Borodyansky's work include Bioactive Compounds and Antitumor Agents (12 papers), Cancer Cells and Metastasis (10 papers) and Cancer Mechanisms and Therapy (6 papers). Laura Borodyansky is often cited by papers focused on Bioactive Compounds and Antitumor Agents (12 papers), Cancer Cells and Metastasis (10 papers) and Cancer Mechanisms and Therapy (6 papers). Laura Borodyansky collaborates with scholars based in United States, Japan and Canada. Laura Borodyansky's co-authors include Johannes Fruehauf, Amy E. Parker, Shuanglin Xiang, Arthur B. Pardee, Lili Huang, Chiang J. Li, Bin Shi, Yutaka Ueda, Youzhi Li and Chiang Li and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Clinical Oncology and British Journal of Cancer.

In The Last Decade

Laura Borodyansky

27 papers receiving 459 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Laura Borodyansky United States 12 267 172 84 79 72 28 470
Armelle Goubard France 13 262 1.0× 221 1.3× 205 2.4× 75 0.9× 29 0.4× 25 586
Karthik M. Kodigepalli United States 12 298 1.1× 63 0.4× 174 2.1× 57 0.7× 74 1.0× 16 525
Corinne Capoulade France 7 195 0.7× 144 0.8× 76 0.9× 17 0.2× 42 0.6× 8 341
Lucas E. Cavallin United States 10 301 1.1× 376 2.2× 278 3.3× 88 1.1× 69 1.0× 12 764
Krisztina Kerekes Hungary 14 206 0.8× 29 0.2× 273 3.3× 24 0.3× 42 0.6× 30 510
Christina Kittipatarin United States 7 107 0.4× 166 1.0× 218 2.6× 7 0.1× 26 0.4× 7 419
Howard J. Leung United States 7 264 1.0× 102 0.6× 193 2.3× 20 0.3× 36 0.5× 8 410
Joanna Stanson United States 15 339 1.3× 205 1.2× 436 5.2× 24 0.3× 156 2.2× 20 715
Gunther Zischinsky Germany 6 114 0.4× 88 0.5× 36 0.4× 18 0.2× 20 0.3× 10 259
Masako Mori Japan 12 236 0.9× 63 0.4× 106 1.3× 49 0.6× 24 0.3× 21 437

Countries citing papers authored by Laura Borodyansky

Since Specialization
Citations

This map shows the geographic impact of Laura Borodyansky's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Laura Borodyansky with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Laura Borodyansky more than expected).

Fields of papers citing papers by Laura Borodyansky

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Laura Borodyansky. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Laura Borodyansky. The network helps show where Laura Borodyansky may publish in the future.

Co-authorship network of co-authors of Laura Borodyansky

This figure shows the co-authorship network connecting the top 25 collaborators of Laura Borodyansky. A scholar is included among the top collaborators of Laura Borodyansky based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Laura Borodyansky. Laura Borodyansky is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
3.
Bekaii‐Saab, Tanios, Alexander Starodub, Bassel F. El‐Rayes, et al.. (2018). Phase 1b/2 trial of cancer stemness inhibitor napabucasin (NAPA) + nab-paclitaxel (nPTX) and gemcitabine (Gem) in metastatic pancreatic adenocarcinoma (mPDAC).. Journal of Clinical Oncology. 36(15_suppl). 4110–4110. 16 indexed citations
4.
Bekaii‐Saab, Tanios, Alexander Starodub, Bassel F. El‐Rayes, et al.. (2017). A phase 1b/II study of cancer stemness inhibitor napabucasin in combination with gemcitabine (gem) & nab-paclitaxel (nabptx) in metastatic pancreatic adenocarcinoma (mpdac) patients (pts). Annals of Oncology. 28. iii150–iii150. 3 indexed citations
5.
Bekaii‐Saab, Tanios, David Goldstein, Takuji Okusaka, et al.. (2017). CanStem111P trial: A phase III study of napabucasin plus nab-paclitaxel (nab-PTX) with gemcitabine (gem) in adult patients with metastatic pancreatic adenocarcinoma (mPDAC). Annals of Oncology. 28. iii136–iii136. 2 indexed citations
6.
Bendell, Johanna C., Joleen M. Hubbard, Bert H. O’Neil, et al.. (2017). Phase 1b/II study of cancer stemness inhibitor napabucasin in combination with FOLFIRI +/− bevacizumab (bev) in metastatic colorectal cancer (mCRC) patients (pts). Annals of Oncology. 28. iii150–iii151. 7 indexed citations
7.
Bendell, Johanna C., Bert H. O’Neil, Alexander Starodub, et al.. (2017). Cancer stemness inhibition and chemosensitization: Phase 1b/II study of cancer stemness inhibitor napabucasin (BBI-608) with FOLFIRI +/- bevacizumab (Bev) administered to colorectal cancer (CRC) patients (pts).. Journal of Clinical Oncology. 35(4_suppl). 593–593. 11 indexed citations
8.
Grothey, Axel, Manish A. Shah, Takayuki Yoshino, et al.. (2017). CanStem303C trial: A phase III study of napabucasin (BBI-608) in combination with 5-fluorouracil (5-FU), leucovorin, irinotecan (FOLFIRI) in adult patients with previously treated metastatic colorectal cancer (mCRC).. Journal of Clinical Oncology. 35(15_suppl). TPS3619–TPS3619. 16 indexed citations
9.
Bendell, Johanna C., Joleen M. Hubbard, Bert H. O’Neil, et al.. (2017). Phase 1b/II study of cancer stemness inhibitor napabucasin (BBI-608) in combination with FOLFIRI +/- bevacizumab (bev) in metastatic colorectal cancer (mCRC) patients (pts).. Journal of Clinical Oncology. 35(15_suppl). 3529–3529. 12 indexed citations
10.
Mason, Warren, Paula de Robles, Laura Borodyansky, et al.. (2017). BBI608-201GBM: A phase Ib/II clinical study of napabucasin (BBI608) in combination with temozolomide (TMZ) for adult patients with recurrent glioblastoma (GBM).. Journal of Clinical Oncology. 35(15_suppl). e13525–e13525. 7 indexed citations
11.
Bekaii‐Saab, Tanios, Chung‐Pin Li, Takuji Okusaka, et al.. (2017). CanStem111P trial: A phase III study of napabucasin (BBI-608) plus nab-paclitaxel (nab-PTX) with gemcitabine (gem) in adult patients with metastatic pancreatic adenocarcinoma (mPDAC).. Journal of Clinical Oncology. 35(15_suppl). TPS4148–TPS4148. 11 indexed citations
12.
13.
Shahda, Safi, Bassel F. El‐Rayes, Bert H. O’Neil, et al.. (2016). A phase Ib study of cancer stem cell (CSC) pathway inhibitor BBI-608 in combination with gemcitabine and nab-paclitaxel (nab-PTX) in patients (pts) with metastatic pancreatic ductal adenocarcinoma (mPDAC).. Journal of Clinical Oncology. 34(4_suppl). 284–284. 6 indexed citations
14.
15.
Hubbard, Joleen M., Derek J. Jonker, Bert H. O’Neil, et al.. (2015). A phase Ib study of BBI608 in combination with FOLFIRI with and without bevacizumab in patients (pts) with advanced colorectal cancer (CRC).. Journal of Clinical Oncology. 33(15_suppl). 3616–3616.
16.
Borodyansky, Laura, et al.. (2009). Genomic instability en route to and from cancer stem cells. Cell Cycle. 8(7). 1000–1002. 35 indexed citations
17.
Parker, Amy E., et al.. (2006). Delivery of RNA Interference. Cell Cycle. 5(18). 2103–2109. 137 indexed citations
18.
Song, Diane H., et al.. (2005). Gastrin stabilises β-catenin protein in mouse colorectal cancer cells. British Journal of Cancer. 92(8). 1581–1587. 11 indexed citations
19.
Borodyansky, Laura, et al.. (1998). Apoptosis in non-proliferating cells: implications for viral infection and tumourigenesis. APOPTOSIS. 3(6). 381–385. 3 indexed citations
20.
Li, Chiang J., Yutaka Ueda, Bin Shi, et al.. (1997). Tat protein induces self-perpetuating permissivity for productive HIV-1 infection. Proceedings of the National Academy of Sciences. 94(15). 8116–8120. 98 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Armelle Goubard Breakdown of academic impact, for papers by Karthik M. Kodigepalli Breakdown of academic impact, for papers by Corinne Capoulade Breakdown of academic impact, for papers by Lucas E. Cavallin Breakdown of academic impact, for papers by Krisztina Kerekes Breakdown of academic impact, for papers by Christina Kittipatarin Breakdown of academic impact, for papers by Howard J. Leung Breakdown of academic impact, for papers by Joanna Stanson Breakdown of academic impact, for papers by Gunther Zischinsky Breakdown of academic impact, for papers by Masako Mori
Rankless by CCL
2026